Invasive pneumococcal infections among persons with and without underlying medical conditions: Implications for prevention strategies

  • Peter Klemets1,

    Affiliated with

    • Outi Lyytikäinen1,

      Affiliated with

      • Petri Ruutu1,

        Affiliated with

        • Jukka Ollgren1 and

          Affiliated with

          • J Pekka Nuorti1, 2Email author

            Affiliated with

            BMC Infectious Diseases20088:96

            DOI: 10.1186/1471-2334-8-96

            Received: 17 April 2008

            Accepted: 22 July 2008

            Published: 22 July 2008

            Abstract

            Background

            The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for persons aged < 65 years with chronic medical conditions. We evaluated the risk and mortality from invasive pneumococcal disease (IPD) among persons with and without the underlying medical conditions which are considered PPV23 indications.

            Methods

            Population-based data on all episodes of IPD (positive blood or cerebrospinal fluid culture) reported by Finnish clinical microbiology laboratories during 1995–2002 were linked to data in national health care registries and vital statistics to obtain information on the patient's preceding hospitalisations, co-morbidities, and outcome of illness.

            Results

            Overall, 4357 first episodes of IPD were identified in all age groups (average annual incidence, 10.6/100,000). Patients aged 18–49 and 50–64 years accounted for 1282 (29%) and 934 (21%) of IPD cases, of which 372 (29%) and 427 (46%) had a current PPV23 indication, respectively. Overall, 536 (12%) IPD patients died within one month of first positive culture. Persons aged 18–64 years accounted for 254 (47%) of all deaths (case-fatality proportion, 12%). Of those who died 117 (46%) did not have a vaccine indication. In a survival model, patients with alcohol-related diseases, non-haematological malignancies, and those aged 50–64 years were most likely to die.

            Conclusion

            In the general population of non-elderly adults, almost two-thirds of IPD and half of fatal cases occurred in persons without a recognised PPV23 indication. Policymakers should consider additional prevention strategies such as lowering the age of universal PPV23 vaccination and introducing routine childhood pneumococcal conjugate immunisation which could provide substantial health benefits to this population through indirect vaccine effects.

            Background

            Streptococcus pneumoniae is a leading cause of serious community-acquired infections such as bacteraemia and meningitis and community-acquired pneumonia. The pneumococcal polysaccharide vaccine (PPV23) is recommended for adults aged 18–64 years with certain chronic medical conditions and elderly persons because of high disease rates and increased risk of death [1, 2]. Available information from representative, population-based studies on the outcome of IPD is limited. Case fatality has generally been defined as in-hospital mortality, without extended follow up after discharge from hospital [1, 2].

            The estimates of PPV23 effectiveness against IPD are highest among otherwise healthy young adults [36], but lower among persons with multiple underlying medical conditions and immunosuppression [7, 8]. In the United States, routine childhood 7-valent pneumococcal conjugate vaccine (PCV7) immunisation program has resulted in dramatic reductions in rates of pneumococcal-related diseases and major changes in the epidemiology of pneumococcal infections in children and adults because of reduced transmission of vaccine types and herd protection in unvaccinated groups [911]. In Finland, however, PCV7 has not been introduced in the national immunisation schedule and the uptake of PPV23 in the recommended target groups has been extremely low (3%) [12].

            We investigated all first episodes of IPD identified by Finnish microbiology laboratories during 1995–2002 and linked these national, population-based surveillance data to other health registries to evaluate the risk and outcome of IPD among patients with various underlying medical conditions with special emphasis on the general population of working-age adults.

            Methods

            Surveillance

            The Finnish National Health Care System is organised into 20 geographically and administratively defined health care districts (HCD), with catchment populations ranging from 68,000 to 1.4 million (total population 5.2 million). All clinical microbiology laboratories are required to notify bacterial isolations from blood and cerebrospinal fluid (CSF), including S. pneumoniae, to the National Infectious Disease Register (NIDR), primarily through electronic reporting. Each notification includes information on the date and type of specimen, date of birth, sex, and place of treatment. Using this information and a time interval of three months, possible multiple positive culture results or notifications concerning the same individual are merged into a single case either by a notifying laboratory or after the notification is received in the NIDR database.

            Study population and definitions

            A case with IPD was defined as isolation of S. pneumoniae from blood and/or CSF during 1995–2002. Of the total of 4611 IPD episodes identified by the primary diagnostic laboratory, only the first episode from each case-patient was included in the analysis (N = 4357); recurrent episodes and those with missing identification information were excluded. Pneumococcal bacteraemia was defined as isolation of S. pneumoniae from blood only and pneumococcal meningitis as isolation of S. pneumoniae from CSF with or without pneumococcal bacteraemia within 7 days. Patients with a vaccine indication were defined as those who had at least one of the underlying medical conditions for which PPV23 is recommended in Finland (Additional file 1). This list of conditions is practically identical to that recommended by the U.S. Advisory Committee on Immunization Practices (ACIP) [13].

            Underlying medical conditions

            Information on co-morbidities and underlying conditions for IPD patients was obtained by linking the IPD surveillance database to the following national population-based registries using the date of the first positive specimen for S. pneumoniae and the national identity code: the Cancer Registry (diagnosis of haematological and non-haematological malignancy within one year and five years prior to the specimen date), National Social Insurance Institution (KELA), National Hospital Discharge Register (HILMO) and NIDR (HIV infection). Presence of diabetes mellitus, chronic pulmonary disease (chronic obstructive pulmonary disease [COPD] and asthma), congenital or acquired immunodeficiency, rheumatic or other autoimmune diseases requiring immunosuppressive therapy, solid organ or bone marrow transplantation, cardiac failure, or renal failure were defined as a KELA record indicating entitlement for reimbursement of medications for these conditions. Alcohol-related diseases (ARD), chronic liver diseases, diseases of the spleen, and CSF leak were defined as records in HILMO with one ore more International Classification of Diseases (ICD), Ninth or 10th Revision (from 1996 onward) coded discharge diagnoses within one year before the first positive specimen date (ICD-codes in Additional file 2).

            Vital status (possible date of death) at 7, 28 and 90 days from the first positive culture of S. pneumoniae for each case-patient was determined from the National Population Information System.

            Calculation of incidence rates and statistical analysis

            Annual population data from the Statistics Finland during 1995–2002 were used as denominators to calculate age- and sex-specific incidence rates. In the same way, the denominators for population at risk in person years for categories of underlying medical conditions were obtained from corresponding national health care registries. Categorical variables were analyzed with the χ2 test or Fisher's exact test. Continuous variables were analyzed by the Mann-Whitney U test. P < .05 was considered to be statistically significant. Piecewise exponential hazard regression model [14] was used in age-group 18–64 years to assess the risk of death with underlying medical conditions for which PPV23 is currently recommended in Finland (Additional file 1), controlling also for other medical underlying conditions, the type of IPD presentation, age and sex. Data were analysed by using SPSS for Windows version 14.0 (Chicago, IL, USA) and Stata 8.2 (College Station, TX, USA).

            Ethical aspects

            Use of data collected from population-based registries in this research was authorised by the Ministry of Social Affairs and Health, the Finnish Data Protection Authority, and the National Research and Development Center for Welfare and Health.

            Results

            Incidence

            During 1995–2002, 4357 first episodes of IPD were identified in all age groups and 2216 (51%) were persons aged 18–64 years; 1282 (29%) and 934 (21%) were aged 18–49 years and 50–64 years, respectively. The average annual incidence of IPD was 10.6 cases per 100,000 persons. The median age of cases was 53 years (range, 0–98 years) and 2536 (58%) were males. The median duration of hospitalisation was 7 days (range, 0–530 days).

            Of the cases in all age groups, 4106 (94%) were bacteraemias and 251 (6%) meningitis. Within the age group 18–64 years, the rates of bacteraemia and meningitis increased 2.5 and 3.3 fold with increasing age (Table 1). The rate of bacteraemia was significantly higher in males than in females in all age groups; for meningitis the rate was higher only in males aged 35–49 years.
            Table 1

            Incidence of Streptococcus pneumoniae bacteraemia and meningitis by age and sex, Finland, 1995–2002

             

            Ratea of bacteraemia (no of cases)

            Ratea of meningitis (no of cases)

            Age group (years)

            Male

            Female

            Total

            Rate ratiob

            95% CIc

            Male

            Female

            Total

            Rate ratiob

            95% CIc

            0–17

            8.3 (386)

            6.0 (299)

            7.2 (685)

            1.4

            1.2–1.6

            0.5 (22)

            0.6 (26)

            0.5 (48)

            0.8

            0.5–1.4

            18–34

            5.7 (265)

            3.2 (142)

            4.5 (407)

            1.8

            1.5–2.2

            0.4 (17)

            0.1 (6)

            0.3 (23)

            4.0

            0.7–10.1

            35–49

            11.3 (544)

            5.3 (245)

            8.4 (789)

            2.1

            1.8–2.5

            0.9 (43)

            0.4 (20)

            0.7 (63)

            2.2

            1.3–3.8

            50–64

            14.6 (546)

            8.2 (314)

            11.4 (860)

            1.8

            1.5–2.0

            1.1 (42)

            0.8 (32)

            1.0 (74)

            1.4

            0.9–2.2

            65–74

            23.0 (349)

            13.9 (275)

            17.9 (624)

            1.7

            1.4–1.9

            0.7 (10)

            0.9 (17)

            0.8 (27)

            0.8

            0.4–1.7

            ≥ 75

            37.4 (304)

            24.1 (437)

            28.2 (741)

            1.6

            1.3–1.8

            1.0 (8)

            0.4 (8)

            0.6 (16)

            2.5

            0.9–6.7

            All

            11.9 (2394)

            8.1 (1712)

            9.9 (4106)

            1.5

            1.4–1.6

            0.7 (142)

            0.5 (109)

            0.6 (251)

            1.4

            1.1–1.8

            aAverage annual incidence (cases per 100,000 population); bmale to female rate ratio; cCI, confidence interval

            Underlying conditions

            In all age-groups, 2302 (53%) of cases had at least one underlying condition, including age ≥ 65 years, for which PPV23 is recommended. However, among working-age patients aged 18–64 years, only 799 (36%) had a PPV23 indication. Of patients aged 18–49 and 50–64 years 372 (29%) and 427 (46%), respectively, had a condition for which PPV23 is currently recommended. Among working-aged persons, alcohol-related diseases, chronic pulmonary disease and diabetes mellitus were the most common vaccine indications whereas cardiac failure, chronic pulmonary disease and diabetes mellitus were most common among elderly patients (Table 2). Persons aged 16–84 years accounted for 96% of cases with alcohol-related diseases. The highest rates of IPD were seen in patients with haematological malignancy and organ or bone marrow transplantation.
            Table 2

            Risk of invasive Streptococcus pneumoniae infection (IPI) associated with selected underlying conditions, Finland, 1995–2002.

            Underlying conditiona

            Number of IPI cases by age group (years)

            Population at risk (person years)

            Rate/100,000/year

            95%CIb

            Case fatality proportion at day 7/28/90

             

            < 18

            18–64

            ≥ 65

            All (%)

                
             

            N = 733

            N = 2216

            N = 1408

            N = 4357

                

            Chronic pulmonary diseasec

            44

            190

            260

            494 (11.3)

            1,435,000

            34.4

            31.4–37.4

            8/12/15

            Cardiac failure

            13

            51

            287

            351 (8.1)

            746,000

            47.1

            42.2–52.0

            16/24/30

            Diabetes mellitus

            3

            140

            186

            329 (7.5)

            1,014,000

            32.5

            29.0–36.0

            13/19/23

               Type 1 diabetesd

            3

            16

            0

            19 (0.4)

            158,000

            12.0

            6.6–17.4

            5/5/5

            Immunodeficiency or rheumatic diseases

            4

            128

            138

            270 (6.2)

            779,000

            34.7

            30.5–38.9

            14/19/22

            Alcohol-related diseases

            0

            241

            10

            251 (5.8)

            1,117,000e

            21.9f

            19.1–24.6

            21/28/33

            Non-haematological malignancy

                    

               < 1 year since diagnosis

            2

            46

            58

            106 (2.4)

            208,000

            50.9

            41.2–60.6

            22/29/41

               < 5 years since diagnosis

            13

            92

            139

            244 (5.6)

            730,000

            33.4

            29.2–37.6

            16/24/33

            Haematological malignancy

                    

               < 1 year since diagnosis

            5

            25

            26

            56 (1.3)

            10,000

            547.2

            398.9–685.5

            14/16/25

               < 5 years since diagnosis

            23

            68

            72

            163 (3.7)

            38,000

            434.5

            367.8–501.2

            10/13/21

            Organ or bone marrow transplantation

            5

            26

            3

            34 (0.8)

            21,000

            163.7

            108.7–218.7

            3/6/9

            Chronic renal failure

            1

            15

            8

            24 (0.6)

            27,000

            88.6

            53.1–124.1

            8/13/17

            Chronic liver disease

            0

            15

            5

            20 (0.5)

            NAg

            NA

            NA

            15/30/35

            HIV infection

            0

            10

            0

            10 (0.2)

            8,000

            129.7

            49.3–210.1

            10/20/30

            aPatient may have more than one underlying condition; bCI, confidence interval; cchronic obstructive pulmonary disease (COPD) and/or bronchial asthma; ddiabetes mellitus diagnosed at age < 30 years and insulin treatment; eextrapolation based on 12 month-prevalence of persons with alcohol use disorders from a representative sample of Finland's adult (≥ 30 years) population [21]; fIPI cases with alcohol-related diseases aged ≥ 30 years (N = 245); gNA, not available

            Mortality

            Of the 4357 cases with IPD, 202 (5%) died on the day of admission, 373 (9%) died within one week, and 536 (12%) within 28 days. An additional 130 cases died between 29–90 days after the first blood- and/or CSF-culture positive for S. pneumoniae (Table 3). Four hundred and thirty-seven (10%) cases died during the hospitalisation for IPD. The in-hospital case-fatality proportions (CFP) within 7, 28 and 90 days were 8%, 10% and 11%, respectively.
            Table 3

            Outcome of Streptococcus pneumoniae bacteraemia and meningitis by age and sex, Finland, 1995–2002.

             

            Number of deaths (case fatality proportion, %)

             

            Bacteremia

            Meningitis

             

            7 days

            28 days

            90 days

            7 days

            28 days

            90 days

            Age group (years)

            Male

            Female

            Male

            Female

            Male

            Female

            Male

            Female

            Male

            Female

            Male

            Female

            0–17

            2 (0.6)

            4 (1.3)

            2 (0.6)

            4 (1.3)

            2 (0.6)

            4 (1.3)

            1 (4.5)

            2 (7.7)

            1 (4.5)

            2 (7.7)

            1 (4.5)

            2 (7.7)

            18–34

            9 (3.4)

            6 (4.2)

            15 (5.7)

            7 (4.9)

            15 (5.7)

            8 (5.6)

            0 (0.0)

            1 (16.7)

            2 (11.8)

            2 (33.3)

            2 (11.8)

            2 (33.3)

            35–49

            43 (7.9)

            22 (8.9)

            59 (10.9)

            27 (11.0)

            67 (12.3)

            33 (13.5)

            4 (9.3)

            3 (15.0)

            8 (18.6)

            4 (20.0)

            9 20.9)

            5 (25.0)

            50–64

            53 (9.7)

            21 (6.7)

            92 (16.7)

            28 (8.9)

            114 (20.9)

            39 (12.4)

            4 (9.5)

            0 (0.0)

            7 (16.7)

            3 (9.4)

            12 (28.6)

            4 (12.5)

            65–74

            39 (11.2)

            26 (9.4)

            55 (15.8)

            37 (13.4)

            76 (21.8)

            47 (17.1)

            2 (20.0)

            4 (23.5)

            3 (30.0)

            5 (29.4)

            3 (30.0)

            5 (29.4)

            ≥ 75

            65 (21.4)

            58 (13.3)

            84 (27.6)

            83 (19.0)

            100 (32.9)

            109 (24.9)

            2 (25.0)

            2 (25.0)

            3 (37.5)

            3 (37.5)

            3 (37.5)

            4 (50.0)

            All

            211 (8.8)

            137 (8.0)

            307 (12.8)

            186 (10.9)

            374 (15.6)

            240 (14.0)

            13 (9.1)

            12 (11.0)

            24 (16.9)

            19 (17.4)

            30 (21.1)

            22 (20.2)

            Of all deaths during the first month, persons aged 18–49 and 50–64 years accounted for 124 (23%) and 130 (24%); CFP were 10% and 14%, respectively. The CFP at 7, 28 and 90 days were similar for both sexes in the age group 18–49 years but significantly higher in men than in women in persons aged 50–64 years at 28 and 90 days (17% vs. 9% and 21% vs. 12%; p < 0.01 for both comparisons). The CFP at days 28 and 90 were significantly higher for meningitis than bacteraemia (p < 0.02).

            In all age-groups, the highest CFP at 28 days were seen among persons with non-haematological malignancy, chronic liver disease, ARD and cardiac failure (Table 2). Of cases aged 18–64 years, who died on the day of culture or during the first week, the median ages were 50 and 48 years, respectively, and the most common underlying medical conditions were ARD, diabetes and immunodeficiency/rheumatic diseases in both groups. Of the fatal cases among persons aged 18–49 years and 50–64 years, 61 (49%) and 76 (59%), respectively, had an underlying condition which is considered a PPV23 indication. The CFP for patients aged 18–64 years with vaccine indication was 17% compared with 8% for patients without an indication (relative risk, 2.1; 95%CI, 1.6–2.6).

            Hospital discharge data in connection with the IPD episode were available for 2132 (96%) of cases aged 18–64 years. We constructed a piecewise exponential hazard regression model to evaluate the risk of dying associated with various underlying medical conditions in this group. In this analysis, 848 (40%) patients had at least one underlying condition for which PPV23 is recommended and 1254 (59%) did not have a PPV23 indication. Of all patients, 477 (22%) had other, non-PPV23 indication discharge diagnosis codes (ICD-9 and ICD-10) given during the IPD episode or diagnosis codes given during previous hospitalisations within one year of the episode. The remaining 807 (38%) cases had neither other diagnoses nor previous hospitalisations and were considered the healthy reference group. The underlying medical conditions for which PPV23 is recommended, other diagnoses for hospitalisations, sex, age (two categories, 18–49 years and 50–64 years) and type of IPD (bacteraemia or meningitis) were included in the model (Table 4). The highest hazard ratios (HR) were seen for ARD, HIV infection and non-haematological malignancy. The HR for male sex, age 50–64 years, meningitis, ARD and haematological malignancy were time-dependent. In ARD the HR was highest during the first week, and it was only significant in meningitis from 8 to 28 days and in haematological malignancy from 29 to 90 days. In the model the HR are multiplicative, e.g. for a male aged 50–64 years with ARD and meningitis the risk of dying within 28 days was 25 times higher compared to 'previously healthy' group (1.6 × 1.3 × 3.2 × 3.8 = 25.3).
            Table 4

            Piecewise exponential hazard regression model for factors associated with death in cases aged 18–64 years with invasive pneumococcal infection

             

            Death at 0–7 days

            Death at 8–28 days

            Death at 29–90 days

            Factor

            Hazard ratio

            95%CIa

            P-value

            Hazard ratio

            95%CIa

            P-value

            Hazard ratio

            95%CIa

            P-value

            Male sex

            0.9

            0.6–1.2

            0.5

            1.6

            1.3–2.0

            < 0.001

            1.6

            1.3–2.0

            < 0.001

            Age > 50 years

            1.3

            1.1–1.7

            < 0.05

            1.3

            1.1–1.7

            < 0.05

            2.8

            2.2–3.5

            < 0.001

            Meningitis

            1.2

            0.7–2.3

            0.7

            3.2

            2.0–5.0

            < 0.001

            0.7

            0.4–1.2

            0.3

            Alcohol-related diseases

            5.6

            3.8–8.1

            < 0.001

            3.8

            2.9–4.9

            < 0.001

            3.8

            2.9–4.9

            < 0.001

            Cardiac failure

            2.6

            1.8–3.8

            < 0.001

            2.6

            1.8–3.8

            < 0.001

            2.6

            1.8–3.8

            < 0.001

            Chronic renal failure

            1.6

            0.5–5.2

            0.4

            1.6

            0.5–5.2

            0.4

            1.6

            0.5–5.2

            0.4

            Chronic liver disease

            4.4

            2.3–8.6

            < 0.001

            4.4

            2.3–8.6

            < 0.001

            4.4

            2.3–8.6

            < 0.001

            HIV infection

            4.8

            2.1–10.9

            < 0.001

            4.8

            2.1–10.9

            < 0.001

            4.8

            2.1–10.9

            < 0.001

            Haematological malignancyb

            0.9

            0.2–3.5

            0.6

            0.9

            0.2–3.5

            0.6

            6.9

            4.1–11.5

            < 0.001

            Non-haematological malignancyb

            4.7

            3.3–6.7

            < 0.001

            4.7

            3.3–6.7

            < 0.001

            4.7

            3.3–6.7

            < 0.001

            Diabetes mellitus

            1.4

            0.9–2.0

            0.13

            1.4

            0.9–2.0

            0.13

            1.4

            0.9–2.0

            0.13

            Chronic pulmonary disease

            1.0

            0.6–1.6

            1.0

            1.0

            0.6–1.6

            1.0

            1.0

            0.6–1.6

            1.0

            Organ/bone marrow transplantation

            0.9

            0.4–1.8

            0.7

            0.9

            0.4–1.8

            0.7

            0.9

            0.4–1.8

            0.7

            Immunodeficiency/rheumatic diseases

            1.7

            1.2–2.2

            < 0.05

            1.7

            1.2–2.2

            < 0.05

            1.7

            1.2–2.2

            < 0.05

            Otherc medical underlying conditions

            1.7

            1.3–2.2

            < 0.001

            1.7

            1.3–2.2

            < 0.001

            1.7

            1.3–2.2

            < 0.001

            Healthy

            Ref.d

              

            Ref.

              

            Ref.

              

            aCI, confidence interval; b < 1 year since cancer diagnosis; cnon-PPV23 indication; dRef., reference

            Discussion

            Data from our national, population-based study indicate that about half of all cases and deaths due to IPD occurred among working-age adults and that only 36% of the cases in this age-group had any of the underlying conditions for which PPV23 is currently recommended. To strengthen the efforts to reduce the high burden of IPD among non-elderly adults, policymakers should consider new prevention strategies to supplement the current recommendations for use of PPV23 to reach the almost two-thirds of cases without a vaccine indication.

            By linking surveillance data to national vital statistics we were able to estimate all-cause mortality up to 3 months following an episode of IPD. Although the CFP was 9% during the first week, mortality at one month in persons with various underlying conditions ranged from 5% to 30% and increased in most groups up to 3 months after the first positive culture, probably reflecting both the severity of the underlying illness and the effects of long term sequelae [15]. The overall mortality was highest for non-haematological malignancy, chronic liver disease, alcohol-related diseases, cardiac failure and HIV infection. Our findings are consistent with two previous population-based studies on IPD and pneumococcal bacteraemic pneumonia in which mortality among persons with underlying medical conditions ranged from 3% to 13% [2] and 6% to 34% [16], respectively. In both studies the highest mortality was observed among persons with cirrhosis and alcohol abuse, coronary artery disease/congestive heart failure and non-haematological malignancies.

            Our survival model for predictors of poor outcome in non-elderly adults indicated that the conditions with highest risk of death were alcohol-related diseases and non-haematological malignancies. The effects of some patient and disease characteristics such as meningitis as the clinical syndrome, age 50–64 years, male sex, ARD and haematological malignancies, seemed time-dependent in predicting death. The hazard ratios for these conditions were either significant only at some time-point in the model or they changed over time. Of all IPD cases, about 5% died during the day of admission and ARD was the most common underlying condition in this group of patients. The hazard ratios for ARD were higher at 0–7 days than at later time points, possibly reflecting delays in hospital admissions and treatment in this patient group.

            In our study as much as 64% of IPD cases among working-age adults did not have any of the underlying conditions for which PPV23 is currently recommended. This proportion is substantially higher than previously reported from the U.S. (41%) [1, 17] but there are few comparable data available from European countries. Alcohol-related diseases were the most frequent (11%) underlying condition in the working-age group as they have been in some other previous studies [18]. The incidence of IPD among persons with ARD in our study, however, was lower (21.9) compared with estimates ranging from 62 to 483.4 per 100,000 population in previous population-based studies [2, 19, 20]. However, because of lower base-line incidence in Finland, difficulties in defining the population at risk for ARD as well as evaluating the accuracy and representativeness of the denominator data used in these studies, the interpretation of the observed differences is complex. Our estimated denominator for ARD was an extrapolation based on the 12-month prevalence of persons with alcohol use disorders from a representative sample of Finnish adult (≥ 30 years) population [21].

            Among patients with various immunocompromising conditions, the rate of IPD varied from 33.4 to 547.2 per 100,000 and was highest in those with haematological malignancy. In immunocompetent patients (persons with diabetes mellitus, chronic pulmonary disease and cardiac failure) there was less variation in rates (range, 12.0–47.1 per 100,000). Previous population-based studies reported higher rates for solid cancer (216.1 to 300.4 per 100,000), chronic pulmonary disease (62.9 to 503 per 100,000) and HIV (422.9 to 2031.4 per 100,000) [2, 19, 20], likely because of differences in population composition, databases, definitions, sources of denominator data and accuracy and completeness of identifying diagnoses of underlying conditions in IPD patients. Previous studies have included malignancies at any time point [2, 20], whereas we restricted those diagnosed less than five or one year, respectively, before the IPD episode. For chronic pulmonary diseases, some studies incorporated only COPD and emphysema cases [19, 20], but we also included asthma. The relatively low rate of IPD among persons infected with HIV in Finland may reflect good access to antiretroviral therapy, early antibiotic treatment without blood cultures and use of prophylactic antibiotics among those with low CD4+ T cell count.

            Although our estimates from national laboratory-based surveillance are representative of the entire population of Finland, the observed IPD incidence was low compared with reports from some other European countries [2224], and the United States [1]. Our previous report from Finland found that the overall average annual incidence of IPD increased by 35.1% during a 8-year study period and increased in all adult age groups [25]. In that study temporal increase and higher regional IPD rates were significantly associated with higher blood culturing rates suggesting that the true incidence of IPD may be higher. Furthermore, although IPD is the most severe manifestation of pneumococcal infections, it represents only a small proportion of the overall burden of pneumococcal disease.

            Of the national registries we used to define the co-morbidities for IPD cases and acquire population-based denominators, the Finnish Cancer Registry has almost 100% coverage [26, 27], and the comprehensiveness of hospital discharge data has been validated previously [2831]. However, our study also has several limitations. First, due to the registry-based study design, our analysis of the clinical outcome lacked chart review data to assess the effect of severity of illness indicators on IPD-related mortality. Information on some underlying conditions may also have been missed. Second, the denominator data for persons with co-morbidities were only available in aggregated form and did not allow estimating age-specific rates in various groups of patients with co-morbidities. Third, it is well known that ICD-coding in hospital discharge data may be incomplete and could be subject to misclassification. For this reason, we used hospital discharge data only to identify underlying conditions (ARD, chronic liver diseases, diseases of the spleen and CSF leakage) for which data were not available in the two other registries where standardised criteria and definitions are used. The standardised reimbursement criteria for underlying conditions in the National Social Insurance Institution's database may have excluded mild cases of certain underlying conditions such as COPD and asthma and diabetes mellitus type 2. Fourth, we did not have information on receipt of pneumococcal polysaccharide vaccination and cigarette smoking habits of patients as some of the associations we found with higher risk of IPD (e.g. alcohol-related diseases and COPD) may be confounded by smoking. About half of invasive pneumococcal disease in immunocompetent non-elderly adults has been previously attributed to cigarette smoking [32].

            In Finland, the coverage of PPV23 among the elderly and high risk groups is about 3% and would not be expected to impact our results. Despite of the existing vaccine recommendation, PPV23 is not included in the government-funded national vaccination program, and the expense is covered by the treating clinical unit or the individual. Two clinical trials have been conducted in Finland to assess the efficacy of PPV23 against pneumonia [33, 34]. The conflicting results from these trials regarding the efficacy in the aged of PPV23 against mainly serologically diagnosed pneumococcal pneumonia, or pneumonia in general probably have also had a major influence on the vaccination coverage.

            The patient groups with highest rates of IPD (e.g. haematological malignancy, organ and bone marrow transplantation, HIV infection) were different from those at highest risk of death (e.g. ARD, non-haematological malignancy and cardiac failure). The almost two-thirds of working-age cases without PPV23 indication, as well as those with alcohol-related diseases may be difficult to reach with public health interventions and acceptability of vaccination may be low among healthy persons. One proposed strategy includes lowering the recommended age for universal PPV23 vaccination to include all persons aged 50 years and older which might result in moderately increased number of IPD cases prevented compared with the current high risk indications [35, 36]. However, given the increasing risk of IPD and mortality with age and the unknown duration of protection after primary immunisation, the optimal timing and frequency of revaccination with PPV23 will need to be determined before this strategy can be implemented. Currently, there are no data available on the clinical effectiveness of revaccination and serologic studies suggest that antibody responses may by lower after revaccination that after primary vaccination [3739].

            Routine childhood immunisation with PCV7 has not yet been introduced in Finland. However, increasing evidence has been accumulating about the substantial indirect effects of childhood PCV7 immunisation in reducing rates of adult pneumococcal disease in the U.S. and elsewhere [40, 41], although early reports from some European countries have had inconsistent results [4245]. The serotypes included in PCV7 cause approximately 50% of IPD in Finnish adults, a proportion similar to the U.S. before PCV7 introduction [25]. Therefore, introducing routine childhood immunisation in Finland would provide an opportunity to substantially reduce the disease burden among the difficult-to-reach groups of working-age adults without PPV23 indications [11].

            Conclusion

            In addition to young children and elderly persons, the burden of invasive pneumococcal infections is also substantial among working-age persons without high risk conditions. In the general population of non-elderly adults, two-thirds of invasive infections and one half of fatal cases occur in persons without a recognised PPV23 indication. Policymakers should therefore consider additional prevention strategies to reduce the burden of pneumococcal disease in the overall population.

            Abbreviations

            ACIP: 

            Advisory Committee on Immunization Practices

            ARD: 

            Alcohol-Related Diseases

            CFP: 

            Case-Fatality Proportion

            CI: 

            Confidence Interval

            COPD: 

            Chronic Obstructive Pulmonary Disease

            CSF: 

            Cerebrospinal Fluid

            HCD: 

            Health Care District

            HILMO: 

            National Hospital Discharge Register

            HR: 

            Hazard Ratio

            ICD: 

            International Classification of Diseases

            IPD: 

            Invasive Pneumococcal Disease

            KELA: 

            National Social Insurance Institution

            NIDR: 

            National Infectious Disease Register

            PCV7: 

            7-valent Pneumococcal Conjugate Vaccine

            PPV23: 

            23-valent Pneumococcal Polysaccharide Vaccine.

            Declarations

            Acknowledgements

            PK acknowledges support by grants from the Finska Läkaresällskapet and the Perklen Foundation. The foundations did not play a role in any aspect of the study or in the writing of this paper.

            The authors are grateful to the staff at Finnish clinical microbiology laboratories for reporting microbiological data. We also wish to thank Eero Pukkala at Cancer Registry and Timo Klaukka at National Social Insurance Institution for valuable advice during the register-linkage. The advice of Matti Ristola at Helsinki University Central Hospital with respect to treatment of HIV patients is acknowledged.

            Authors’ Affiliations

            (1)
            Department of Infectious Disease Epidemiology and Control, National Public Health Institute (KTL)
            (2)
            Respiratory Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC)

            References

            1. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG: Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998 – Opportunities for prevention in the conjugate vaccine era. JAMA 2001,285(13):1729–1735.PubMedView Article
            2. Kyaw MH, Christie P, Clarke SC, Mooney JD, Ahmed S, Jones IG, Campbell H: Invasive Pneumococcal Disease in Scotland, 1999–2001: Use of Record Linkage to Explore Associations between Patients and Disease in Relation to Future Vaccination Policy. Clin Infect Dis 2003,37(10):1283–1291.PubMedView Article
            3. Shapiro ED, Clemens JD: A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984,101(3):325–330.PubMed
            4. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS: The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988,108(5):653–657.PubMed
            5. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, Anglim AM: Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995,155(21):2336–2340.PubMedView Article
            6. Moberley S, Holden J, Tatham D, Andrews R: Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, 1:CD000422.PubMed
            7. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD: The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine. N Engl J Med 1991,325(21):1453–1460.PubMedView Article
            8. Forrester HL, Jahnigen DW, LaForce FM: Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987,83(3):425–430.PubMedView Article
            9. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003,348(18):1737–1746.PubMedView Article
            10. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG: Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005,294(16):2043–2051.PubMedView Article
            11. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR: Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007,369(9568):1179–1186.PubMedView Article
            12. Ruutu P, Kuusi M, Nuorti PJ, Koskinen S: Communicable diseases. Health and functional capacity in Finland Baseline results of the Health 2000 examination survey (Edited by: Aromaa A, Koskinen S). Helsinki: National Public Health Institute 2004, B12:67–69.
            13. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR Recomm Rep 1997,46(RR-8):1–24.
            14. Friedman M: Piecewise exponential models for survival data with covariates. Annals of Statistics 1982,10(1):101–113.View Article
            15. Austrian R, Gold J: Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964, 60:759–776.PubMed
            16. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGreer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000,90(2):223–229.PubMedView Article
            17. Whitney CG, Schaffner W, Butler JC: Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis 2001,33(5):662–675.PubMedView Article
            18. Schoenmakers MCJ, Hament JM, Fleer A, Aerts PC, van Dijk H, Kimpen JLL, Wolfs TFW: Risk factors for invasive pneumococcal disease. Reviews in Medical Microbiology 2002,13(1):29–36.
            19. Pastor P, Medley F, Murphy TV: Invasive pneumococcal disease in Dallas County, Texas: Results from population-based surveillance in 1995. Clin Infect Dis 1998,26(3):590–595.PubMedView Article
            20. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG: The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005,192(3):377–386.PubMedView Article
            21. Pirkola SP, Isometsa E, Suvisaari J, Aro H, Joukamaa M, Poikolainen K, Koskinen S, Aromaa A, Lonnqvist JK: DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population–results from the Health 2000 Study. Soc Psychiatry Psychiatr Epidemiol 2005,40(1):1–10.PubMedView Article
            22. Ortqvist A: Pneumococcal disease in Sweden: experiences and current situation. Am J Med 1999,107(1A):44S-49S.PubMedView Article
            23. Konradsen HB, Kaltoft MS: Invasive pneumococcal infections in denmark from 1995 to 1999: epidemiology, serotypes, and resistance. Clin Diagn Lab Immunol 2002,9(2):358–365.PubMed
            24. Pedersen MK, Hoiby EA, Froholm LO, Hasseltvedt V, Lermark G, Caugant DA: Systemic pneumococcal disease in Norway 1995–2001: capsular serotypes and antimicrobial resistance. Epidemiol Infect 2004,132(2):167–175.PubMedView Article
            25. Klemets P, Lyytikäinen O, Ruutu P, Kaijalainen T, Leinonen M, Ollgren J, Nuorti JP: Trends and geographical variation in invasive pneumococcal infections in Finland. Scand J Infect Dis 2008,40(8):621–628.PubMedView Article
            26. Teppo L, Pukkala E, Lehtonen M: Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994,33(4):365–369.PubMedView Article
            27. Brenner H, Hakulinen T: Reduction in selective under-ascertainment bias in population-based estimates of cancer patient survival by age adjustment. Eur J Cancer 2005,41(12):1788–1793.PubMedView Article
            28. Mahonen M, Miettinen H, Pyorala K, Molarius A, Salomaa V, Kuulasmaa K: Hospital discharge register data in the assessment of trends in acute myocardial infarction. FINMONICA AMI Register Study Team. Ann Med 1995,27(5):547–554.PubMedView Article
            29. Mahonen M, Salomaa V, Brommels M, Molarius A, Miettinen H, Pyorala K, Tuomilehto J, Arstila M, Kaarsalo E, Ketonen M, Kuulasmaa K, Lehto S, Mustaniemi H, Niemela M, Palomaki P, Torppa J, Vuorenmaa T: The validity of hospital discharge register data on coronary heart disease in Finland. Eur J Epidemiol 1997,13(4):403–415.PubMedView Article
            30. Mahonen M, Salomaa V, Torppa J, Miettinen H, Pyorala K, Immonen-Raiha P, Niemela M, Ketonen M, Arstila M, Kaarsalo E, Lehto S, Mustaniemi H, Palomaki P, Puska P, Vuorenmaa T, Tuomilehto J: The validity of the routine mortality statistics on coronary heart disease in Finland: comparison with the FINMONICA MI register data for the years 1983–1992. Finnish multinational MONItoring of trends and determinants in CArdiovascular disease. J Clin Epidemiol 1999,52(2):157–166.PubMedView Article
            31. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari P, Mahonen M, Niemela M, Kuulasmaa K, Palomaki P, Mustonen J, Lehtonen A, Arstila M, Vuorenmaa T, Lehto S, Miettinen H, Torppa J, Tuomilehto J, Kesaniemi YA, Pyorala K, Salomaa V: The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005,12(2):132–137.PubMedView Article
            32. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF: Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000,342(10):681–689.PubMedView Article
            33. Koivula I, Sten M, Leinonen M, Makela PH: Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997,103(4):281–290.PubMedView Article
            34. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, Leinonen M, Kivela SL, Makela PH: Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999,17(20–21):2493–2500.PubMedView Article
            35. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG: Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race. Ann Intern Med 2003,138(12):960–968.PubMed
            36. Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM: Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001–2003. Clin Infect Dis 2006,43(2):141–150.PubMedView Article
            37. Mufson MA: Antibody response of pneumococcal vaccine: need for booster dosing? Int J Antimicrob Agents 2000,14(2):107–112.PubMedView Article
            38. Lackner TE, G Hamilton R, Hill J, Davey C, Guay DRP: Pneumococcal Polysaccharide Revaccination: Immunoglobulin G Seroconversion, Persistence, and Safety in Frail, Chronically Ill Older Subjects. J Am Geriatr Soc 2003,51(2):240–245.PubMedView Article
            39. Torling J, Hedlund J, Konradsen HB, Ortqvist A: Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003,22(1):96–103.PubMedView Article
            40. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003MMWR Morb Mortal Wkly Rep 2005,54(36):893–897.
            41. Vila-Corcoles A: Advances in Pneumococcal Vaccines: What are the Advantages for the Elderly? Drugs Aging 2007,24(10):791–800.PubMedView Article
            42. Cumulative weekly number of reports of Invasive Pneumococcal Disease due to any of the seven serotypes in Prevenar™: Children aged < 2 Years in England and Wales by Epidemiological Year: July-June (2003- To Date)[http://​www.​hpa.​org.​uk/​webw/​HPAweb&​HPAwebStandard/​HPAweb_​C/​1207821645727?​p=​1203409671876]
            43. Vestrheim DF, Lovoll O, Aaberge IS, Caugant DA, Hoiby EA, Bakke H, Bergsaker MR: Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008.
            44. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R: Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008,46(2):174–182.PubMedView Article
            45. Dias R, Canica M: Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol 2007,51(1):35–42.PubMedView Article
            46. Pre-publication history

              1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2334/​8/​96/​prepub

            Copyright

            © Klemets et al. 2008

            This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.